Biotech | April 29, 2022
Moderna files for authorization of its Covid-19 vaccine in young children six months to six years
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
If authorized by the USFDA, the Proof Lab Test System may be used to deliver accurate, actionable, lab-quality results for Covid-19 in as little as 18 minutes
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Subscribe To Our Newsletter & Stay Updated
